---
schema_version: "secwatch.filing_event.v1"
accession: "0001549595-24-000086"
form_type: "8-K"
ticker: "NRIX"
cik: "0001549595"
company_name: "Nurix Therapeutics, Inc."
filed_at: "2024-06-17T23:59:59+00:00"
generated_at: "2026-06-01T04:05:52.704565+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Nurix Therapeutics: NX-5948 achieves 69.2% ORR in Phase 1 CLL; pivotal trial planned for 2025

## Summary
- Objective response rate of 69.2% in 26 evaluable CLL patients across 50-600 mg daily doses; responses deepened over time.
- Heavily pretreated population: median 4 prior therapies (96.8% BTKi, 90.3% BCL2i, 25.8% non-covalent BTKi).
- 43.3% had BTK mutations, 20% PLCG2 mutations, 46.7% TP53 mutations; CNS involvement in 2 patients responded.
- NX-5948 well tolerated; common adverse events: purpura/contusion, thrombocytopenia, neutropenia.
- Company plans to initiate pivotal, registration-directed trial(s) for NX-5948 in 2025.

## SEC filing metadata
- accession: 0001549595-24-000086
- form_type: 8-K
- ticker: NRIX
- cik: 0001549595
- company_name: Nurix Therapeutics, Inc.
- filed_at: 2024-06-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1549595/000154959524000086/0001549595-24-000086-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1549595/000154959524000086/nrix-20240616.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001549595-24-000086
- JSON: https://secwatch.observer/filing/0001549595-24-000086.json
- Plain text: https://secwatch.observer/filing/0001549595-24-000086.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.